Clinical Trials / Research Studies

DIPG/High Grade Glioma Relapse / Refractory

PBTC-045: A Safety and Preliminary Efficacy trial of MK-3475 (pembrolizumab; anti-PD-1) in Children with recurrent, progressive or refractory high-grade gliomas (HGG) and DIPGs

• Ages: From 1 to 21 years old

This clinical trial studies the side effects and best dose of pembrolizumab and to see how well it works in treating younger patients with high-grade gliomas (brain tumors) or diffuse intrinsic pontine gliomas (brain stem tumors) that have come back, progressed, or have not responded to previous tre ...More

PBTC-048: Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma

PURPOSE: This feasibility trial studies how well the Optune device works in treating younger patients with recurrent/refractory/progressive supratentorial malignant glioma and ependymoma. The TTFields generated by Optune device may inhibit the growth of tumor.&#x2028 DETAILED DESCRIPTION: Primary Ob ...More

PBTC-060: A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

• Ages: 1 Year to 21 Years

This is a multicenter pilot study of SurVaxM (SVN53-67/M57-KLH) for children and young adults with progressive or relapsed medulloblastoma, high grade glioma, ependymoma and newly diagnosed diffuse intrinsic pontine glioma. Survivin (BIRC5) is an inhibitor of apoptosis (IAP) protein that is highly e ...More

PEPN2111: CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

• Ages: 1 Month to 30 Years

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block sig ...More

Volitinib in Treating Participants with Recurrent or Refractory Medulloblastoma, High-Grade Glioma, or Diffuse Intrinsic Pontine Glioma

• Ages: 6 Years to 21 Year

This phase I trial studies the best dose and side effect of volitinib in treating participants with Medulloblastoma, High-Grade Glioma or Diffuse Intrinsic Pontine Glioma that have come or does not respond to treatment. Volitinib may stop the growth of tumor cells by blocking some of the enzymes nee ...More